Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 186

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management

Open access
Adhami, Vaqar Mustafa, Syed, Deeba Nadeem, Khan, Naghma, Mukhtar, Hasan·2012·Biochemical Pharmacology

Abstract

Epidemiologic and case control population based studies over the past few decades have identified diet as an important determinant of cancer risk. This evidence has kindled an interest into research on bioactive food components and has till date resulted in the identification of many compounds with cancer preventive and therapeutic potential. Among such compounds has been fisetin (3,7,3’,4’-tetrahydroxyflavone), a flavonol and a member of the flavonoid polyphenols that also include quercetin, myricetin and kaempferol. Fisetin is commonly found in many fruits and vegetables such as apples, persimmons, grapes, kiwis, strawberries, onions and cucumbers. We evaluated the effects of fisetin against melanoma and cancers of the prostate, pancreas and the lungs. Using prostate and lung adenocarcinoma cells, we observed that fisetin acts as a dual inhibitor of the PI3K/Akt and the mTOR pathways. This is a significant finding considering the fact that mTOR is phosphorylated and its activation is more frequent in tumors with overexpression of PI3K/Akt. Dual inhibitors of PI3K/Akt and mTOR signaling have been suggested as valuable agents for treating such cancers. Here, we summarize our findings on the dietary flavonoid fisetin and its effects on cancer with particular focus on prostate cancer. Our observations and findings from other laboratories suggest that fisetin could be a useful chemotherapeutic agent that could be used either alone or as an adjuvant with conventional chemotherapeutic drugs for the management of prostate and other cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bcp.2012.07.012

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 45

  1. Khan, 2008, Cancer chemoprevention through dietary antioxidants: progress and promise, Antioxid Redox Signal, 10, 475, 10.1089/ars.2007.1740 · DOI · Paper page
  2. Moon, 2006, Dietary flavonoids: effects on xenobiotic and carcinogen metabolism, Toxicol In Vitro, 20, 187, 10.1016/j.tiv.2005.06.048 · DOI · Paper page
  3. Kimira, 1998, Japanese intake of flavonoids and isoflavonoids from foods, J Epidemiol, 8, 168, 10.2188/jea.8.168 · DOI · Paper page
  4. Shia, 2009, Metabolism and pharmacokinetics of 3,3′,4′,7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites, J Agric Food Chem, 57, 83, 10.1021/jf802378q · DOI
  5. Maher, 2007, A novel approach to screening for new neuroprotective compounds for the treatment of stroke, Brain Res, 1173, 117, 10.1016/j.brainres.2007.07.061 · DOI
  6. Ishige, 2001, Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms, Free Radic Biol Med, 30, 433, 10.1016/S0891-5849(00)00498-6 · DOI · Paper page
  7. Gabor, 1966, Antibacterial effect of fisetin and fisetinidin, Nature, 212, 1273, 10.1038/2121273a0 · doi:10.1038/2121273a0
  8. Sagara, 2004, Induction of PC12 cell differentiation by flavonoids is dependent upon extracellular signal-regulated kinase activation, J Neurochem, 90, 1144, 10.1111/j.1471-4159.2004.02563.x · DOI
  9. Maher, 2006, Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory, Proc Natl Acad Sci USA, 103, 16568, 10.1073/pnas.0607822103 · DOI · Paper page
  10. Zheng, 2008, Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity, Int Immunopharmacol, 8, 484, 10.1016/j.intimp.2007.12.012 · DOI · Paper page
  11. Sung, 2007, Mol Pharmacol, 71, 1703, 10.1124/mol.107.034512 · DOI · Paper page
  12. Touil, 2009, Flavonoid-induced morphological modifications of endothelial cells through microtubule stabilization, Nutr Cancer, 61, 310, 10.1080/01635580802521346 · DOI
  13. Salmela, 2009, Dietary flavonoid fisetin induces a forced exit from mitosis by targeting the mitotic spindle checkpoint, Carcinogenesis, 30, 1032, 10.1093/carcin/bgp101 · DOI
  14. Chen, 2002, Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1, Arch Toxicol, 76, 351, 10.1007/s00204-002-0346-6 · DOI · Paper page
  15. Lee, 2002, Wogonin and fisetin induce apoptosis in human promyeloleukemic cells, accompanied by a decrease of reactive oxygen species, and activation of caspase 3 and Ca(2+)-dependent endonuclease, Biochem Pharmacol, 63, 225, 10.1016/S0006-2952(01)00876-0 · DOI · Paper page
  16. Liao, 2009, Involvement of the ERK signaling pathway in fisetin reduces invasion and migration in the human lung cancer cell line A549, J Agric Food Chem, 57, 8933, 10.1021/jf902630w · DOI
  17. Ravichandran, 2011, Fisetin, a novel flavonol attenuates benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice, Food Chem Toxicol, 49, 1141, 10.1016/j.fct.2011.02.005 · DOI
  18. Suh, 2009, A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways, Carcinogenesis, 30, 300, 10.1093/carcin/bgn269 · DOI · Paper page
  19. Chen, 2010, Enhancement of p53-mutant human colorectal cancer cells radiosensitivity by flavonoid fisetin, Int J Radiat Oncol Biol Phys, 77, 1527, 10.1016/j.ijrobp.2010.02.043 · doi:10.1016/j.ijrobp.2010.02.043
  20. Lu, 2005, Fisetin inhibits the activities of cyclin-dependent kinases leading to cell cycle arrest in HT-29 human colon cancer cells, J Nutr, 135, 2884, 10.1093/jn/135.12.2884 · DOI
  21. Yu, 2011, Securin depletion sensitizes human colon cancer cells to fisetin-induced apoptosis, Cancer Lett, 300, 96, 10.1016/j.canlet.2010.09.015 · doi:10.1016/j.canlet.2010.09.015
  22. Murtaza, 2009, Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB, Int J Cancer, 125, 2465, 10.1002/ijc.24628 · DOI
  23. Hiipakka, 2002, Structure–activity relationships for inhibition of human 5alpha-reductases by polyphenols, Biochem Pharmacol, 63, 1165, 10.1016/S0006-2952(02)00848-1 · DOI · Paper page
  24. Haddad, 2010, Antiproliferative mechanisms of the flavonoids 2,2′-dihydroxychalcone and fisetin in human prostate cancer cells, Nutr Cancer, 62, 668, 10.1080/01635581003605524 · DOI
  25. Afaq, 2008, Inhibition of epidermal growth factor receptor signaling pathway by delphinidin, an anthocyanidin in pigmented fruits and vegetables, Int J Cancer, 123, 1508, 10.1002/ijc.23675 · doi:10.1002/ijc.23675
  26. Khan, 2008, Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells, Carcinogenesis, 29, 1049, 10.1093/carcin/bgn078 · DOI · Paper page
  27. Khan, 2008, A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice, Cancer Res, 68, 8555, 10.1158/0008-5472.CAN-08-0240 · DOI · Paper page
  28. Chien, 2010, Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells, Mol Cell Biochem, 333, 169, 10.1007/s11010-009-0217-z · DOI
  29. Suh, 2010, Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells, Carcinogenesis, 31, 1424, 10.1093/carcin/bgq115 · DOI · Paper page
  30. Malik, 2002, Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer, Clin Cancer Res, 8, 1168
  31. McMenamin, 1999, Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage, Cancer Res, 59, 4291
  32. Kremer, 2006, Expression of mTOR signaling pathway markers in prostate cancer progression, Prostate, 66, 1203, 10.1002/pros.20410 · DOI · Paper page
  33. Gioeli, 2005, Signal transduction in prostate cancer progression, Clin Sci (Lond), 108, 293, 10.1042/CS20040329 · DOI
  34. Gioeli, 1999, Activation of mitogen-activated protein kinase associated with prostate cancer progression, Cancer Res, 59, 279
  35. Abreu-Martin, 1999, Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer, Mol Cell Biol, 19, 5143, 10.1128/MCB.19.7.5143 · DOI · Paper page
  36. Gao, 2006, Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer, Proc Natl Acad Sci USA, 103, 14477, 10.1073/pnas.0606836103 · DOI · Paper page
  37. Uzgare, 2004, Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells, Cancer Res, 64, 6190, 10.1158/0008-5472.CAN-04-0968 · DOI
  38. Kinkade, 2008, Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model, J Clin Invest, 118, 3051
  39. Khan, 2012, Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin, Int J Cancer, 130, 1695, 10.1002/ijc.26178 · DOI
  40. Dowling, 2010, mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs, Science, 328, 1172, 10.1126/science.1187532 · DOI · Paper page
  41. Webber, 2001, Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression, Prostate, 47, 1, 10.1002/pros.1041 · DOI
  42. Tripathi, 2011, Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors, Mol Cancer Ther, 10, 255, 10.1158/1535-7163.MCT-10-0606 · DOI
  43. Kandaswami, 1993, Ascorbic acid-enhanced antiproliferative effect of flavonoids on squamous cell carcinoma in vitro, Anticancer Drugs, 4, 91, 10.1097/00001813-199302000-00012 · DOI
  44. Touil, 2011, Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice, Cancer Chemother Pharmacol, 68, 445, 10.1007/s00280-010-1505-8 · DOI
  45. Szliszka, 2011, The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells, Int J Oncol, 39, 771

Cited by

See all 186

Metadata

Authors
Adhami, V. M., Syed, D. N., Khan, N., & Mukhtar, H.
Venue
Biochemical Pharmacology
Publisher
Elsevier BV
Published
2012-11
Volume
84
Issue
10
Pages
1277-1281
ISSN
0006-2952 (ISSN-L)
OpenAlex
W2036380534
Cited by
186
References
3
FWCI
8.05
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
United States Public Health Service (RO1 CA 160867)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. https://app.cochat.ai/papers/10.1016/j.bcp.2012.07.012
The paper
Adhami, V. M., Syed, D. N., Khan, N., & Mukhtar, H. (2012). Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2012.07.012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.